Perspective Therapeutics (CATX) Payables (2011 - 2026)

Perspective Therapeutics has disclosed Payables across 16 years of filings, most recently posting $29.5 million for Q2 2026.

• In Q2 2026, Payables rose 315.02% year-over-year to $29.5 million; the TTM figure through Jun 2026 stood at $29.5 million (up 315.02% YoY), while the FY2025 annual figure was $20.6 million, up 97.85% from the prior year.
• Payables came in at $29.5 million for Q2 2026 at Perspective Therapeutics, up from $26.5 million in the prior quarter.
• In the past five years, Payables ranged from a high of $29.5 million in Q2 2026 to a low of $769000.0 in Q1 2022.
• Average Payables over 5 years is $9.8 million, with a median of $6.6 million recorded in 2023.
• Year-over-year, Payables jumped 458.47% in 2024 and sank 39.61% in 2025.
• Over 5 years, Payables stood at $1.5 million in 2022, then soared by 351.52% to $7.0 million in 2023, then soared by 49.4% to $10.4 million in 2024, then jumped by 97.85% to $20.6 million in 2025, then soared by 43.31% to $29.5 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $29.5 million in Q2 2026, $26.5 million in Q1 2026, and $20.6 million in Q4 2025.